For this Series paper, we used several search approaches. We searched the Cochrane Library, Medline, and Embase using the search term “COPD” in combination with “clinical trial”, “effectiveness”, or “systematic review”, for 1 year between Jan 1, 2014 and Feb 28, 2015. For the years preceding this search we used the bibliography cited in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) document (GOLD search strategy used COPD, filters “human”, “all adult”, or “items” with
SeriesCurrent concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management
Introduction
Chronic obstructive pulmonary disease (COPD) is a common, complex, and heterogeneous condition that is responsible for substantial and growing morbidity, mortality, and health-care expenses worldwide.1 In this context, complexity relates to many different components with non-linear dynamic interactions, whereas heterogeneity implies that not all of these components are present in all patients at any given timepoint or in the same patient at different timepoints.2 To address this complexity and heterogeneity, identification of groups of patients with similar clinical characteristics, prognosis or treatment needs (so-called clinical phenotypes), is imperative.3 On one hand, this strategy is logical for research because it might create an increasingly homogeneous selection of patients in whom to decipher the complexity of COPD. On the other hand, this strategy might be of restricted clinical value because, first, clinical phenotypes can overlap in the same patient and, second, the same clinical phenotype could result from different biological mechanisms (ie, aetiological heterogeneity). Although the development of therapeutic approaches has increasingly attempted to address these complexities, so far most treatment options belong to a restricted number of pharmacological classes—ie, bronchodilators (eg, short-acting beta-2 agonists [SABA] and long-acting beta-2 agonists [LABA]), antimuscarinics (eg, short-acting antimuscarinic agent [SAMA] and long-acting antimuscarinic agent [LAMA]), and inhaled corticosteroids.
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) was established in 1998 to improve the diagnosis, management, and prevention of COPD. A challenge for GOLD has since been to provide recommendations for the correct use of the available treatments and at the same time to flexibly position recommendations to allow the use of future innovative treatments that have the potential to target a personalised medicine approach. Another challenge faced by GOLD and other guideline or strategy documents is the paucity of evidence on how clinicians can identify patients who are most likely to benefit from available COPD treatments. This difficulty underlines the need for new treatment approaches in conjunction with refining of the way treatment indications are established. Finally, in most patients COPD is associated with other chronic diseases, a factor that should be addressed globally. This comorbidity might decrease the likelihood that treatments targeting only the COPD component will change the natural history of a patient's disease.
This Series paper addresses the strengths and limitations, including gaps in the evidence, of the approaches taken to move treatment of COPD towards personalised medicine, and also addresses potential future approaches to position emerging treatments that will probably target specific biological pathways. As such, we review the concept of an endotype, a subtype of a clinical disorder defined by a distinct pathophysiological mechanism,4 because it could be associated with future COPD treatments, and also review the role of biomarkers in marking endotypes and directing treatment.
Section snippets
GOLD revolution
The GOLD 20015 and 20066 reports used airflow limitation alone (as assessed by the forced expiratory volume in 1 s [FEV1] value) to assess disease severity. Bronchodilators were recommended as treatments to improve lung function and reduce symptoms in all patients, with inhaled corticosteroids reserved for patients with severe and very severe airflow limitation and repeated exacerbations. In 2011, the GOLD document acknowledged that use of FEV1 alone to assess disease severity was an overly
COPD endotypes
As previously discussed, an endotype4 is a subtype of a clinical disorder defined by a distinct pathophysiological mechanism, whereas a clinical phenotype3 is a single or combination of disease attributes that describe differences between individuals with COPD as they relate to clinically meaningful outcomes (ie, symptoms, exacerbations, response to treatment, rate of disease progression, or death; figure 2). In the past decade, studies aiming to identify and characterise subpopulations of
Conclusions and future directions
We will gain empiric knowledge from proof-of-concept trials in COPD with emerging drugs that target specific inflammatory pathways (eg, monoclonal antibodies against interleukins 4, 5, 6, 13, 17, and 1β).96 Yet, at least two reasons exist for caution as these clinical trials are approached. First, a given endotype might possibly be relevant for only a small subset of the population with this disease. If so, these trials will have to consider either enrolment of only people who are likely to
Search strategy and selection criteria
References (107)
- et al.
Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome
J Allergy Clin Immunol
(2011) - et al.
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study
Lancet Respir Med
(2013) - et al.
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial
Lancet
(2015) - et al.
Inhaled steroids in COPD: when should they be used?
Lancet Respir Med
(2014) - et al.
Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations
Respir Med
(2014) - et al.
Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials
Lancet Respir Med
(2013) - et al.
Glucocorticoid resistance in inflammatory diseases
Lancet
(2009) - et al.
Integrating real-life studies in the global therapeutic research framework
Lancet Respir Med
(2013) - et al.
α-1-Antitrypsin deficiency: clinical variability, assessment, and treatment
Trends Mol Med
(2014) - et al.
Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial
Lancet
(2000)
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study
Lancet Respir Med
Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD
Chest
Procalcitonin-guided antibiotic therapy in COPD exacerbations: closer but not quite there
Chest
Identification of airway bacterial colonization by an electronic nose in chronic obstructive pulmonary disease
Respir Med
Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis
Am J Med
Association between pathogens detected using quantitative polymerase chain reaction with airway inflammation in COPD at stable state and exacerbations
Chest
Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD
Chest
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary
Am J Respir Crit Care Med
The path to personalised medicine in COPD
Thorax
Chronic obstructive pulmonary disease phenotypes: the future of COPD
Am J Respir Crit Care Med
Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease NHLBI/WHO workshop
Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease
Characterisation of COPD heterogeneity in the ECLIPSE cohort
Respir Res
A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC)
Prim Care Respir J
Chronic Obstructive Pulmonary Disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
Formoterol and tiotropium compared with tiotropium alone for treatment of COPD
COPD
Evaluation of changes in guidelines for medication management of stable chronic obstructive pulmonary disease
J Eval Clin Pract
QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease
Drugs
Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
Cochrane Database Syst Rev
Susceptibility to exacerbation in chronic obstructive pulmonary disease
N Engl J Med
INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD
Eur Respir J
Inhaled corticosteroids for stable chronic obstructive pulmonary disease
Cochrane Database Syst Rev
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial
BMJ
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
Eur Respir J
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
N Engl J Med
Withdrawal of inhaled corticosteroids in individuals with COPD—a systematic review and comment on trial methodology
Respir Res
Withdrawal of inhaled glucocorticoids and exacerbations of COPD
N Engl J Med
Inhaled glucocorticoids and COPD exacerbations
N Engl J Med
Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study
Am J Respir Crit Care Med
Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial
Thorax
Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
Cochrane Database Syst Rev
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial
Ann Intern Med
The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide
Am J Respir Crit Care Med
Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease
Cochrane Database Syst Rev
Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
Cochrane Database Syst Rev
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis
Cochrane Database Syst Rev
Personalized Respiratory Medicine: Exploring the Horizon, Addressing the Issues. Summary of a BRN-AJRCCM Workshop Held in Barcelona on June 12, 2014
Am J Respir Crit Care Med
A 4-year trial of tiotropium in chronic obstructive pulmonary disease
N Engl J Med
Small-airway obstruction and emphysema in chronic obstructive pulmonary disease
N Engl J Med
Corticosteroid reversibility in COPD is related to features of asthma
Am J Respir Crit Care Med
Cited by (194)
COPD and multimorbidity: recognising and addressing a syndemic occurrence
2023, The Lancet Respiratory MedicineAsthma and COPD: distinct diseases or components of a continuum?
2023, Asthma in the 21st Century: New Research AdvancesIL-33 in COPD: the hunt for responder subgroups
2022, The Lancet Respiratory MedicinePathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene–environment interactions across the lifespan
2022, The Lancet Respiratory MedicineApplication of personalized medicine to obstructive sleep apnea in China
2021, Sleep MedicineCitation Excerpt :And the concept of personalized medicine has widened our perspective among respiratory clinicians in recent years. For instance, the identification of phenotypes of asthma or chronic obstructive pulmonary disease (COPD) has improved the way for diagnosis and been developed innovative treatments [69,70]. Compared to traditional therapy, personalized medicine increased efficacy and improved outcomes.